BioAtla Partners with GATC Health to Utilize Disruptive AI to Advance Phase 3 Cancer Treatment and Co-Develop Longevity Therapeutic

January 8, 2026—GATC Health and BioAtla (Nasdaq: BCAB) have partnered to advance late-stage development of a promising cancer drug, Oz-V, and to launch a new longevity-focused company, Inversagen AI. GATC Health and BioAtla will share ownership in Oz-V and any new age-related disease treatments created by applying GATC Health’s AI platform and longevity research to BioAlta’s senescence and longevity technologies to create new intellectual property. 

Jay M. Short, Ph.D., Chairman and CEO of BioAtla, said, “We are excited to announce this partnership with GATC Health. Their Operon™ AI platform uncovers opportunities for novel drugs, including new uses for our drug candidates, and predicts clinical outcomes with nearly 90% accuracy, paving the way for smarter capital allocation decisions. It’s their rapid discovery engine that greatly accelerates and de-risks the traditionally slow and risky drug discovery and development process.”

The initial focus of the collaboration will be to advance Oz-V in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma (OPSCC), with contracts for funding in place. OPSCC accounts for roughly 20-35% of head and neck cancers in many regions with a market value for therapeutics of approximately $1.3 billion. 

In addition, GATC Health’s Operon platform has identified ways to augment BioAtla assets to create what each believe will be a breakthrough approach in longevity therapeutics. A recent market report on “longevity and anti-senescence therapy” estimates a global market size of about USD 27.15 billion in 2024. This market is expected to grow to more than USD 47.6 billion by 2033, with a CAGR of nearly 12%, according to Precedence Research.

As GATC Health’s CTO, Jayson Uffens, noted in a recent joint press announcement, “This is an important partnership for us as it provides a near-term commercial opportunity in OPSCC, as well as laying the foundation to advance the mission of Inversagen AI to cure age-related diseases. BioAtla’s CAB platform offers a novel, highly specific approach to senolytic therapy with the potential to overcome major limitations of current strategies that often harm beneficial senescent cells. Enabling the selective removal of inflamed, pathogenic senescent cells positions us at the forefront of advances in the treatment of longevity and age-related disease.”

About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.